Meanwhile, access to Wegovy has improved slightly compared to last year, due in part to CVS Caremark’s decision to prefer Wegovy on its standard formulary.

In a study of more than 1,600 adults with type 2 diabetes, those who received the highest dose of orforglipron on average shed 10.5% of their weight.

An oral GLP-1 significantly lowered body weight and HbA1c at 72 weeks for adults with overweight or obesity and type 2 ...

Lilly said it’s moving ‘with urgency toward global regulatory submissions to potentially meet the needs of patients who are ...

Eli Lilly shares gained Tuesday as results from a new study moved the drugmaker closer to applying for approval of its ...

With around 73 percent of Americans enjoying their daily coffee fix, it’s natural to wonder how your morning cup might ...

Former athlete Serena Williams shared that she has lost 31 pounds due to a medication. The tennis champion has been opening ...

While Truist Securities analysts said the results from the ATTAIN-2 trial leave “room for competition," they also pointed to ...

Eli Lilly has announced to go for global approval by the end of 2015 after completing the successful trials. The once-daily ...

Makers of weight-loss drugs are expected to rake in more than $150 billion in revenue by the early 2030s, thanks to the ever-growing popularity of Eli Lilly's Zepbound and Novo Nordisk's Wegovy.

Lilly announces positive trial results for its pill form GLP-1 medication, paving the way for global regulatory approval this ...

The results of the ATTAIN-2 study, which involved people with obesity or overweight with type 2 diabetes, showed that the ...